RION Expands Advisory Board to Foster Innovation
RION, a clinical-stage company that specializes in regenerative medicine through exosome-based therapies, has made significant progress with the recent appointment of five distinguished experts to its Advisory Board. This strategic enhancement is designed to boost the company's innovative capabilities and deepen its expertise in regenerative medicine.
Introducing New Expertise at RION
The new Advisory Board members bring a rich tapestry of experience across many medical fields, including orthopedic and plastic surgery, infectious diseases, military medicine, and health strategy for government. Their combined knowledge strengthens RION's position in developing advanced regenerative therapies.
“We are excited to welcome this distinguished group of experts to our team,” said Dr. Atta Behfar, Co-Founder of RION. “Their outstanding backgrounds in clinical practice, public health leadership, biomanufacturing, and scientific innovation will play a vital role in expanding our groundbreaking platform technology and delivering transformative regenerative therapies to patients around the globe.”
Meet the New Advisory Board Members
The newly appointed advisory members are:
- James B. Peake, M.D. - A retired Lieutenant General, Dr. Peake served as the U.S. Army Surgeon General and has extensive experience in military and public service, including a significant role as Secretary of the U.S. Department of Veterans Affairs.
- Raquel C. Bono, M.D., MBA, FACS - Dr. Bono is a groundbreaking trauma surgeon from the Navy, known for her significant leadership roles, which include managing military treatment facilities and serving on Humana's board.
- Steven L. Moran, M.D. - As a Professor at the Mayo Clinic, Dr. Moran is celebrated for his contributions to plastic surgery and regenerative medicine, especially in tissue engineering innovations.
- Andrew Omidvar, Ph.D. - Currently with Philips Healthcare, Dr. Omidvar is a leader in healthcare innovation, focusing on major funding projects and strategic partnerships.
- Steve Reed, Ph.D. - The co-founder and CEO of HDT Bio, Dr. Reed has made significant impacts in infectious disease and vaccine development and has a strong track record of obtaining substantial research grants.
RION's Vision
RION has its roots in the Mayo Clinic, emerging from over twenty years of dedicated research in the Van Cleve Cardiac Regenerative Medicine Program. Discoveries surrounding the crucial role of exosome signaling in tissue repair guided RION’s innovative methods in regenerative medicine.
Based in Rochester, MN, RION is known globally for its advancements in isolating and producing stable platelet-derived regenerative exosomes, identified as PEP™. The company is actively progressing its proprietary biologic PEP™ platform through various clinical trials targeting critical therapeutic areas such as wound healing, cardiology, and orthopedics.
Frequently Asked Questions
What is RION's primary focus?
RION's main goal is to advance exosome-based therapeutics in regenerative medicine, utilizing cutting-edge technology to improve patient care.
Who are the new members of RION's Advisory Board?
The new members of the Advisory Board include Dr. James Peake, Dr. Raquel Bono, Dr. Steven Moran, Dr. Andrew Omidvar, and Dr. Steve Reed, each contributing a wealth of knowledge from their respective medical specialties.
How does RION choose its advisors?
RION selects its advisors based on their extensive experience, healthcare leadership, and significant contributions to the medical community, ensuring a well-rounded and knowledgeable Advisory Board.
Where is RION headquartered?
RION is located in Rochester, MN, where it continues to drive innovation and develop new therapeutic options.
What are the applications for RION's PEP™ technology?
RION's PEP™ technology is currently being assessed in clinical trials for applications in areas like wound healing, cardiology, orthopedics, and beyond, with the goal of transforming the landscape of regenerative medicine.
